Myocardial Ischemia - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 62

Myocardial Ischemia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Myocardial Ischemia - Pipeline Review, H2 2012', provides an overview of the Myocardial Ischemia therapeutic pipeline. This report provides information on the therapeutic development for Myocardial Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myocardial Ischemia. 'Myocardial Ischemia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Myocardial Ischemia.
- A review of the Myocardial Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myocardial Ischemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Myocardial Ischemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Myocardial Ischemia Therapeutic Products under Development, Key Players in Myocardial Ischemia Therapeutics, Myocardial Ischemia Pipeline Overview, Myocardial Ischemia Pipeline, Myocardial Ischemia Pipeline Assessment

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Myocardial Ischemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Myocardial Ischemia 8
Myocardial Ischemia Therapeutics under Development by Companies 10
Myocardial Ischemia Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Myocardial Ischemia Therapeutics – Products under Development by Companies 17
Myocardial Ischemia Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Myocardial Ischemia Therapeutics Development 19
Cardium Therapeutics, Inc. 19
Baxter International Inc. 20
Cook Medical Incorporated 21
CardioVascular BioTherapeutics, Inc. 22
Phage Biotechnology Corporation 23
Viromed Co., Ltd. 24
Biopeutics co., Ltd. 25
Myocardial Ischemia – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Generx - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
FGF-1 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
VM202 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Mesenchymal Stromal Cells - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Papeilin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
FGF-1141 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Prednisone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Evasin-3 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Red Blood Cell Transfusion - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Endocardial Stem Cells - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Autologous Muscle Derived Cells Transplantation - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Adult Autologous CD34+ Stem Cells - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
MANF - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Autologous Bone-Marrow Mononuclear Cells - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
REC 01 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Myocardial Ischemia Therapeutics – Drug Profile Updates 49
Myocardial Ischemia Therapeutics – Discontinued Products 53
Myocardial Ischemia Therapeutics - Dormant Products 54
Myocardial Ischemia – Product Development Milestones 55
Featured News & Press Releases 55
Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study 55
Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition 56
Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease 57
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 59
Apr 24, 2008: International Research Team Publishes Details Of TB4's Cardioprotective Effects In Ischemia-Reperfusion Study 59
Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Tables
Number of Products Under Development for Myocardial Ischemia, H2 2012 8
Products under Development for Myocardial Ischemia – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Cardium Therapeutics, Inc., H2 2012 19
Baxter International Inc., H2 2012 20
Cook Medical Incorporated, H2 2012 21
CardioVascular BioTherapeutics, Inc., H2 2012 22
Phage Biotechnology Corporation, H2 2012 23
Viromed Co., Ltd., H2 2012 24
Biopeutics co., Ltd., H2 2012 25
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Myocardial Ischemia Therapeutics – Drug Profile Updates 49
Myocardial Ischemia Therapeutics – Discontinued Products 53
Myocardial Ischemia Therapeutics – Dormant Products 54

List of Figures
Number of Products under Development for Myocardial Ischemia, H2 2012 8
Products under Development for Myocardial Ischemia – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Intermittent Claudication - Pipeline Review, H2 2012
• Brain Ischemia - Pipeline Review, H1 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Allergic Asthma - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Atherosclerosis - Pipeline Review, H2 2012
• Epilepsy - Pipeline Review, H2 2012